Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Debt Repayments (2022 - 2025)

Cytokinetics (CYTK) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.8 million for FY2025, 24.54% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $4.8 million at Cytokinetics, up from $2.7 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $47.7 million in Q1 2022, with the low at $705000.0 in Q1 2024.
  • Average Long-Term Debt Repayments over 3 years is $10.2 million, with a median of $2.7 million recorded in 2024.
  • Peak annual rise in Long-Term Debt Repayments hit 280.43% in 2025, while the deepest fall reached 280.43% in 2025.
  • Over 3 years, Long-Term Debt Repayments stood at $47.7 million in 2022, then tumbled by 94.42% to $2.7 million in 2024, then surged by 80.62% to $4.8 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $4.8 million, $2.7 million, and $2.7 million for Q4 2025, Q1 2025, and Q3 2024 respectively.